Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of continuous versus fixed-duration daratumumab + lenalidomide + dexamethasone in first-relapse multiple myeloma
2018-004330-15Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall survival at 4 years. Started Dec 2018; status: active.
02
Drugs
daratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-004330-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004330-15.